UnitedHealth Group's (NYSE:UNH) stock has shown significant growth,
jumping 11% over the week, despite its earnings growth tracking behind five-year shareholder returns. Insider sales have seen CAO Thomas E. Roos and EVP Erin Mcsweeney selling 2,851 and 1,500 shares respectively. Despite continued pressures from cyberattack costs, the
stock has rallied, triggering raised price targets from Deutsche Bank, Truist Financial, and Royal Bank of Canada among others. The
Q2 2024 results have also beaten expectations, with a strong performance from the Optum Unit being highlighted. The stock has also been upgraded to 'Buy' by Jefferies Financial Group, StockNews.com and others. Robust financials seem to be driving the stock's recent rally, with the Q2 earnings beating estimates by $0.14 EPS. Despite the positive performance, investors are being urged to contact Levi & Korsinsky before July 15, 2024 to discuss potential rights. Cyberattack impacts continue to weigh on results, but an 89% ownership of shares by institutional owners and a recent dip taken advantage of by ClearBridge All Cap Growth Strategy indicate enduring interest in the stock.
Unitedhealth Group Incorporated UNH News Analytics from Tue, 16 Jan 2024 08:00:00 GMT to Sun, 21 Jul 2024 16:43:21 GMT -
Rating 7
- Innovation -3
- Information 8
- Rumor -6
